Trump's Plan to Lower Drug Prices
Digest more
Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen next.
Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels could result in 15% operating profit cuts in the industry.
Merck & Co has filed a lawsuit against ... and Human Services will be able to negotiate the prices of selected drugs with a “high budget impact” provided via Medicare Parts B and D, starting ...
Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, expand access, and save more lives, the company says. But by shifting patients to a version protected by newer patents,
Shares of U.S. drugmakers rebounded on Monday after an initial selloff as analysts said that President Donald Trump's sweeping executive order to slash prescription drug prices would be difficult to implement and face legal challenges.
I initiate coverage on Merck & Co., Inc. with a Strong Buy rating ... and evolving U.S. drug pricing reform as signs of thesis risk. I value MRK at 17.0x FY26E EPS of $8.18 to arrive at my $ ...
Patients will likely eventually see higher prices and drug shortages under President Trump's plan to assess tariffs on prescription drug imports.
Still, Merck said it is watching for any mid- to long-term impact of FDA layoffs ... including its looking into matching far lower prices paid for drugs in other developed countries.
Merck & Co is on the ... The big challenge will be to target the drug effectively, and intervening with it early enough in the course of infection to have an impact on the virus.
Feedback